MTOR and Hodgkins lymphoma: Finally, metronomic low-dose chemotherapy facilitates edited non-oncogene addiction, namely the successful use of repurposed targeted therapies, e.g., mTOR inhibitors, associated with resolution of M-CRAC in r/r Hodgkin’s lymphoma and consecutive cCR [13,17,45,57].